Perceptive Advisors - Q2 2013 holdings

$992 Million is the total value of Perceptive Advisors's 92 reported holdings in Q2 2013. The portfolio turnover from Q1 2013 to Q2 2013 was - .

 Value Shares↓ Weighting
AEGR NewAEGERION PHARMACEUTICALS INC$226,341,0003,573,426
+100.0%
22.82%
SRPT NewSAREPTA THERAPEUTICS INC$103,521,0002,722,088
+100.0%
10.44%
NBIX NewNEUROCRINE BIOSCIENCES INC$67,993,0005,081,717
+100.0%
6.86%
BIIB NewBIOGEN IDEC INC$49,772,000231,282
+100.0%
5.02%
IBB NewISHARES TRput$46,843,000269,400
+100.0%
4.72%
ACRX NewACELRX PHARMACEUTICALS INC$46,428,0005,008,400
+100.0%
4.68%
GILD NewGILEAD SCIENCES INC$40,419,000788,360
+100.0%
4.08%
REGN NewREGENERON PHARMACEUTICALS$31,328,000139,310
+100.0%
3.16%
TSRO NewTESARO INC$30,137,000920,494
+100.0%
3.04%
EXAS NewEXACT SCIENCES CORP$22,945,0001,649,558
+100.0%
2.31%
CSU NewCAPITAL SR LIVING CORP$21,305,000891,408
+100.0%
2.15%
VRTX NewVERTEX PHARMACEUTICALS INC$20,539,000256,547
+100.0%
2.07%
NEPT NewNEPTUNE TECHNOLOGIES BIORESO$17,602,0005,422,920
+100.0%
1.78%
SRPT NewSAREPTA THERAPEUTICS INCput$14,950,000393,000
+100.0%
1.51%
STML NewSTEMLINE THERAPEUTICS INC$14,105,000591,650
+100.0%
1.42%
SNTA NewSYNTA PHARMACEUTICALS CORP$13,439,0002,693,236
+100.0%
1.36%
ACAD NewACADIA PHARMACEUTICALS INC$13,188,000726,629
+100.0%
1.33%
SNTS NewSANTARUS INC$13,156,000625,000
+100.0%
1.33%
CELG NewCELGENE CORP$11,260,00096,256
+100.0%
1.14%
HCA NewHCA HOLDINGS INC$11,127,000308,560
+100.0%
1.12%
CHTP NewCHELSEA THERAPEUTICS INTL LT$10,714,0004,658,680
+100.0%
1.08%
SRPT NewSAREPTA THERAPEUTICS INCcall$10,461,000275,000
+100.0%
1.06%
SLXP NewSALIX PHARMACEUTICALS INC$9,807,000148,250
+100.0%
0.99%
CLVS NewCLOVIS ONCOLOGY INC$9,433,000140,827
+100.0%
0.95%
P103PS NewNPS PHARMACEUTICALS INC$8,498,000562,400
+100.0%
0.86%
SHPG NewSHIRE PLCsponsored adr$7,685,00080,800
+100.0%
0.78%
OPTR NewOPTIMER PHARMACEUTICALS INCput$7,184,000496,500
+100.0%
0.72%
AET NewAETNA INC NEW$7,169,000112,825
+100.0%
0.72%
ELN NewELAN PLCadr$6,830,000483,000
+100.0%
0.69%
ASTX NewASTEX PHARMACEUTICALS INC$6,779,0001,649,423
+100.0%
0.68%
SPNC NewSPECTRANETICS CORP$6,310,000337,797
+100.0%
0.64%
DYAX NewDYAX CORP$5,960,0001,722,502
+100.0%
0.60%
ATHX NewATHERSYS INC$5,775,0003,479,206
+100.0%
0.58%
CRIS NewCURIS INC$4,442,0001,392,564
+100.0%
0.45%
KMDA NewKAMADA LTD$4,407,000394,860
+100.0%
0.44%
F113PS NewCOVIDIEN PLC$4,242,00067,500
+100.0%
0.43%
SQNM NewSEQUENOM INC$4,148,000985,180
+100.0%
0.42%
NBIX NewNEUROCRINE BIOSCIENCES INCput$4,014,000300,000
+100.0%
0.40%
IMMU NewIMMUNOMEDICS INC$4,021,000739,144
+100.0%
0.40%
RPRX NewREPROS THERAPEUTICS INC$3,347,000181,430
+100.0%
0.34%
ANAC NewANACOR PHARMACEUTICALS INC$3,258,000582,835
+100.0%
0.33%
ARNA NewARENA PHARMACEUTICALS INCput$3,028,000393,200
+100.0%
0.30%
ITMN NewINTERMUNE INC$2,886,000300,000
+100.0%
0.29%
GILD NewGILEAD SCIENCES INCput$2,476,00048,300
+100.0%
0.25%
QCOR NewQUESTCOR PHARMACEUTICALS INCcall$2,272,00050,000
+100.0%
0.23%
CSBR NewCHAMPIONS ONCOLOGY INC RSTD$1,989,0001,808,244
+100.0%
0.20%
BDSI NewBIODELIVERY SCIENCES INTL IN$1,939,000477,600
+100.0%
0.20%
QCOR NewQUESTCOR PHARMACEUTICALS INC$1,917,00042,186
+100.0%
0.19%
NBS NewNEOSTEM INC$1,840,0003,315,938
+100.0%
0.19%
INFI NewINFINITY PHARMACEUTICALS INC$1,813,000111,940
+100.0%
0.18%
ANTH NewANTHERA PHARMACEUTICALS INC$1,598,0003,451,655
+100.0%
0.16%
SGEN NewSEATTLE GENETICS INCput$1,573,00050,000
+100.0%
0.16%
CEMP NewCEMPRA INC$1,554,000200,000
+100.0%
0.16%
MGCD NewMGC DIAGNOSTICS CORP$1,457,000174,449
+100.0%
0.15%
VPHM NewVIROPHARMA INC$1,384,00048,300
+100.0%
0.14%
PGNX NewPROGENICS PHARMACEUTICALS IN$1,368,000306,650
+100.0%
0.14%
VICL NewVICAL INCcall$1,252,000400,000
+100.0%
0.13%
TKMR NewTEKMIRA PHARMACEUTICALS CORP$1,244,000270,000
+100.0%
0.12%
AMRN NewAMARIN CORP PLCput$1,119,000193,000
+100.0%
0.11%
CYCC NewCYCLACEL PHARMACEUTICALS INC$1,033,000350,000
+100.0%
0.10%
BMR NewBIOMED REALTY TRUST INC$1,012,00050,000
+100.0%
0.10%
ECYT NewENDOCYTE INC$903,00068,806
+100.0%
0.09%
TBIO NewTRANSGENOMIC INC$883,0002,207,500
+100.0%
0.09%
UPI NewUROPLASTY INC$619,000299,113
+100.0%
0.06%
LPDX NewLIPOSCIENCE INC$575,00082,292
+100.0%
0.06%
MDGN NewMEDGENICS INC$570,000150,000
+100.0%
0.06%
EPZM NewEPIZYME INC$506,00018,000
+100.0%
0.05%
CUTR NewCUTERA INC$421,00047,869
+100.0%
0.04%
STEM NewSTEMCELLS INC$382,000231,600
+100.0%
0.04%
KERX NewKERYX BIOPHARMACEUTICALS INC$374,00050,000
+100.0%
0.04%
SNSS NewSUNESIS PHARMACEUTICALS INC$301,00058,010
+100.0%
0.03%
ARRY NewARRAY BIOPHARMA INC$88,00019,320
+100.0%
0.01%
NAVB NewNAVIDEA BIOPHARMACEUTICALS Iput$53,00020,000
+100.0%
0.01%
UNH NewUNITEDHEALTH GROUP INC$21,000315
+100.0%
0.00%
WOOF NewVCA ANTECH INC$20,000780
+100.0%
0.00%
HRC NewHILL ROM HLDGS INC$20,000590
+100.0%
0.00%
WCG NewWELLCARE HEALTH PLANS INC$21,000385
+100.0%
0.00%
V107SC NewWELLPOINT INC$21,000255
+100.0%
0.00%
CI NewCIGNA CORPORATION$21,000290
+100.0%
0.00%
DGX NewQUEST DIAGNOSTICS INC$20,000325
+100.0%
0.00%
OCR NewOMNICARE INC$20,000425
+100.0%
0.00%
HNGR NewHANGER INC$20,000630
+100.0%
0.00%
HLS NewHEALTHSOUTH CORP$20,000695
+100.0%
0.00%
HMA NewHEALTH MGMT ASSOC INC NEWcl a$20,0001,265
+100.0%
0.00%
MOH NewMOLINA HEALTHCARE INC$20,000550
+100.0%
0.00%
MD NewMEDNAX INC$21,000225
+100.0%
0.00%
ENDP NewENDO HEALTH SOLUTIONS INC$19,000530
+100.0%
0.00%
AMSG NewAMSURG CORP$20,000565
+100.0%
0.00%
MDAS NewMEDASSETS INC$20,0001,150
+100.0%
0.00%
MGLN NewMAGELLAN HEALTH SVCS INC$20,000365
+100.0%
0.00%
ALR NewALERE INC$20,000800
+100.0%
0.00%
CBMXW NewCOMBIMATRIX CORPORATION*w exp 05/01/201$1,0005,000
+100.0%
0.00%
Original filings

The following EDGAR filing(s) were analyzed to create this report:

  • View 13F-HR filed 2013-08-14
Signatures

The EDGAR filing(s) were signed by:

About Perceptive Advisors

Perceptive Advisors is a New York-based hedge fund that specializes in healthcare investments. The company was founded in 1999 by Joseph Edelman, who serves as the CEO and Chief Investment Officer. Since its inception, Perceptive Advisors has become one of the most successful healthcare-focused hedge funds in the world, with over $5 billion in assets under management.

The company's investment strategy is based on a deep understanding of the healthcare industry and a focus on identifying promising companies with innovative products and technologies. Perceptive Advisors invests in a wide range of healthcare sectors, including biotechnology, pharmaceuticals, medical devices, and healthcare services.

One of the key factors behind Perceptive Advisors' success is its team of experienced professionals. In addition to Joseph Edelman, the company's leadership team includes Adam Stone, the COO, and Jeremy Goldberg, the Chief Scientific Officer. The team also includes a group of highly skilled analysts and researchers who are experts in their respective fields.

Perceptive Advisors has a strong track record of generating high returns for its investors. However, it is important to note that investing in hedge funds carries significant risks, and investors should carefully consider their investment objectives and risk tolerance before investing. As with any investment, it is important to conduct thorough research and seek the advice of a qualified financial advisor before making any investment decisions.

It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.

Top long-term holdings
NameQuarters ownedLatest quarter ownedMax weighting
NEUROCRINE BIOSCIENCES SHARES42Q3 202315.7%
AMICUS THERAPEUTICS SHARES39Q3 202314.0%
ALDEYRA THERAPEUTICS SHARES35Q3 20233.3%
QUOTIENT TECHNOLOGY INC34Q3 20222.7%
GLOBAL BLOOD THERAPEUTICS SHARES29Q3 20229.3%
ADMA BIOLOGICS SHARES29Q3 20231.4%
RETROPHIN SHARES28Q3 20205.5%
DBV TECHNOLOGIES SA-SPON ADR28Q3 20211.8%
VBI VACCINES SHARES27Q1 20232.8%
IOVANCE BIOTHERAPEUTICS INC26Q3 20239.1%

View Perceptive Advisors's complete holdings history.

Latest significant ownerships (13-D/G)
Perceptive Advisors Q2 2013 significant holdings filed using form 13D/G when ownership exceeds 5% of a company's total stock issue.
FiledShares Percentage
CHEMBIO DIAGNOSTICS, INC.Sold outMay 04, 202300.0%
VBI Vaccines Inc/BCApril 07, 202343,509,55316.7%
Landos Biopharma, Inc.March 30, 202314,869,91547.7%
REATA PHARMACEUTICALS INCMarch 07, 20232,083,7996.5%
AGILE THERAPEUTICS INCSold outFebruary 14, 202300.0%
ALBIREO PHARMA, INC.February 14, 20231,757,1608.5%
BELLUS Health Inc.February 14, 20238,891,0277.1%
CinCor Pharma, Inc.February 14, 20232,576,3255.9%
Coherus BioSciences, Inc.Sold outFebruary 14, 202300.0%
CONCERT PHARMACEUTICALS, INC.February 14, 20231,800,0003.6%

View Perceptive Advisors's complete significant-ownership history.

Latest filings
TypeFiled
SC 13D2024-03-20
SC 13G2024-03-14
SC 13G2024-03-11
SC 13G/A2024-03-06
SC 13D/A2024-03-01
SC 13G2024-03-01
SC 13D/A2024-02-29
13F-HR/A2024-02-26
SC 13G/A2024-02-23
42024-02-21

View Perceptive Advisors's complete filings history.

Compare quarters

Export Perceptive Advisors's holdings